NCT00908180View on ClinicalTrials.gov

Carmustine, Etoposide, Cytarabine, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

PHASE2UnknownINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

July 31, 2014

Conditions
Lymphoma
Interventions
BIOLOGICAL

alemtuzumab

BIOLOGICAL

donor lymphocytes

DRUG

carmustine

DRUG

cyclosporine

DRUG

cytarabine

DRUG

etoposide

DRUG

melphalan

PROCEDURE

allogeneic hematopoietic stem cell transplantation

Sponsors

Lead Sponsor

Cancer Research UK
All Listed Sponsors
lead

Cancer Research UK

OTHER